NYSE American · Biotechnology · USD
Armata Pharmaceuticals, Inc. (ARMP) Stock Analysis
Armata Pharmaceuticals, Inc. (ARMP) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ARMP Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.21
- Previous Close
- $3.20
- Day's Range
- 2.94–3.17
- 52-Week Range
- 2.75–16.34
- Volume
- 93.56K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.41
Valuation
- Market Cap
- $113.78M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 20.53
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −5.29
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$173.80M
- Shares Outstanding
- 37.18M
- 1-Year Return
- −11.82%
Dividend and dates
- Earnings Date
- November 11, 2026estimated
- Avg Volume
- 189.77K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ARMP closed at $3.06, −11.82% over 1 year.
Armata Pharmaceuticals, Inc. (ARMP) has a market capitalization of $113.78M.
In fiscal 2025, ARMP reported revenue of $0.00.
ARMP Stock Return by Calendar Year
Armata Pharmaceuticals, Inc. (ARMP) 10-year return: what $10,000 became
- 1 year
- $10,000 $8,818
- −11.82%
- 5 years
- $10,000 $9,871
- −1.29%
- 10 years
- $10,000 $171
- −98.29%
If you had invested $10,000 in Armata Pharmaceuticals, Inc. (ARMP) 10 years ago, at the close on October 21, 2016, it would have been worth $171 at the close on October 21, 2026: −98.29% in total, −33.44% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −51.27% |
| 2025 | +239.46% |
| 2024 | −42.90% |
| 2023 | +161.29% |
| 2022 | −77.37% |
| 2021 | +83.89% |
| 2020 | −8.31% |
| 2019 | +10.54% |
| 2018 | −79.21% |
| 2017 | −77.05% |
| 2016 (partial year) | −78.11% |
As of October 21, 2026.
ARMP Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$173.80M | — |
| 2024 | $0.00 | −$18.92M | — |
| 2023 | $0.00 | −$69.05M | — |
| 2022 | $0.00 | −$36.92M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$31.22M | −$173.80M | — |
| 2024 | $0.00 | — | −$42.44M | −$18.92M | — |
| 2023 | $0.00 | — | −$40.89M | −$69.05M | — |
| 2022 | $0.00 | — | −$36.95M | −$36.92M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
ARMP Valuation vs Biotechnology Median
Median of 608 stocks| Metric | ARMP | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 20.53 | 13.30 | 54% above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
YahooArmata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
BenzingaArmata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
YahooHC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target
BenzingaArmata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02
BenzingaArmata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Yahoo
All 12 articles ↓Show fewer ↑
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
InvestorsHubArmata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
YahooArmata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02
BenzingaArmata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
YahooArmata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
YahooArmata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B